The EMA’s human medicines committee (CHMP) says the antiviral drug can be used on compassionate-use grounds for people with severe coronavirus complications, such as pneumonia, acute respiratory ...
The EMA's human medicines committee has recommended approval of Johnson & Johnson's Tecvayli as a fourth-line therapy for multiple myeloma, joining a growing group of BCMA-targeted therapies for ...
GlobalData on MSN4mon
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPAThe European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended approving ...
Submission supported by positive results from global, Phase 3 4WHIM clinical trial; U.S. regulatory approval in WHIM syndrome ...
Unveiling oncology and non-oncology drug approvals and withdrawals of USFDA and EMA,” published in the January 2025 issue of ...
X4 Pharmaceuticals (XFOR) announced that its Marketing Authorization Application for mavorixafor for the treatment of WHIM syndrome, a rare ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback